Literature DB >> 20037202

Cytotoxic studies of anti-neoplastic drugs on human lymphocytes--in vitro studies.

I Vamshi Krishna1, G R Vanaja, N Srihari Kirmani Kumar, G Suman.   

Abstract

All the anti-cancer drugs proved to be highly cytotoxic agents to normal cells like lymphocyte cells used in our study which do not come under rapidly dividing cells like bone marrow cells, fetal cells, germ cells, hair follicle cells, intestinal cells, etc. but will proliferate when maintained in growth media with proliferation agents. In this investigation, we determined the effect of anti-cancer drugs on lymphocyte cultures from peripheral blood of healthy non-smoking donors under in vitro conditions by employing MTT assay. All the experiments were carried out with seven anti-cancer drugs; Carboplatin, Avastin, Vinorelbine, Tamoxifen Citrate, Methotrexate, Gemcitabine and Paclitaxel which are broad-spectrum cancer drugs and being used in six different types of chemotherapy in cancers. We have documented the results that were evaluated by statistical analysis. The MTT assay is now widely adopted by researchers and industry, as it is a rapid spectrophotometric method for determining cell viability in cell lines and in vitro. The initial or dose-finding studies determine the drug toxicity relative to dose and subsequent studies define the spectrum of activity of the drug. And moreover, no anti-neoplastic drug is devoid of side effects. Hence, this investigation determines the lethal concentrations and thereby the dosages at which individual anti-neoplastic drugs and also combinations can bring about certain degree of cytotoxicity in human lymphocytes which with comparative study on cancer cell lines would be useful in defining drug dosages.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20037202     DOI: 10.3233/CBM-2009-0111

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  3 in total

1.  Base-modified thymidines capable of terminating DNA synthesis are novel bioactive compounds with activity in cancer cells.

Authors:  Kayla M Borland; Safnas F AbdulSalam; Morwena J Solivio; Matthew P Burke; Patrick R Wolfkiel; Sean M Lawson; Courtney A Stockman; Joel M Andersen; Skyler Smith; Julia N Tolstolutskaya; Purujit N Gurjar; Aron P Bercz; Edward J Merino; Vladislav A Litosh
Journal:  Bioorg Med Chem       Date:  2015-02-14       Impact factor: 3.641

2.  Degradation of NF-κB, p53 and other regulatory redox-sensitive proteins by thiol-conjugating and -nitrosylating drugs in human tumor cells.

Authors:  Ameya Paranjpe; Kalkunte S Srivenugopal
Journal:  Carcinogenesis       Date:  2013-01-25       Impact factor: 4.944

3.  4-Nerolidylcatechol: apoptosis by mitochondrial mechanisms with reduction in cyclin D1 at G0/G1 stage of the chronic myelogenous K562 cell line.

Authors:  Polyana Lopes Benfica; Renato Ivan de Ávila; Bruna Dos Santos Rodrigues; Alane Pereira Cortez; Aline Carvalho Batista; Marilisa Pedroso Nogueira Gaeti; Eliana Martins Lima; Kênnia Rocha Rezende; Marize Campos Valadares
Journal:  Pharm Biol       Date:  2017-12       Impact factor: 3.503

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.